These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
6. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024 [TBL] [Abstract][Full Text] [Related]
7. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging. Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268 [TBL] [Abstract][Full Text] [Related]
8. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic Performance of Margel D; Bernstine H; Groshar D; Ber Y; Nezrit O; Segal N; Yakimov M; Baniel J; Domachevsky L Radiology; 2021 Nov; 301(2):379-386. PubMed ID: 34463555 [TBL] [Abstract][Full Text] [Related]
10. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [TBL] [Abstract][Full Text] [Related]
11. [PET-CT and PET-MRI of the prostate : From Knorr K; Eiber M; Maurer T; Wester HJ; Scheidhauer K Radiologe; 2017 Aug; 57(8):631-636. PubMed ID: 28688023 [TBL] [Abstract][Full Text] [Related]
12. New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography. Afaq A; Batura D; Bomanji J Int Urol Nephrol; 2017 May; 49(5):803-810. PubMed ID: 28197764 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330 [TBL] [Abstract][Full Text] [Related]
14. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061 [TBL] [Abstract][Full Text] [Related]